

"The information provided in this newsletter is for educational and informational purposes only. Any new process, procedure, medication, or clinical trial should be discussed with your primary care physician before being considered or implemented."

Monthly COPD Newsletter

Month/Year: November 2025

Monthly Research Spotlight: COPD Breakthroughs & Local Trial Access

November 2025 Edition

New Hope for COPD Patients: Latest FDA Approvals

COPD treatment is entering a new era with two major therapeutic advancements:

Nucala (mepolizumab) – Now FDA Approved

Approval Date: May 2025

Developer: GlaxoSmithKline

Indication: Add-on maintenance therapy for adults with eosinophilic COPD


Mechanism: Targets IL-5 to reduce eosinophilic inflammation

Clinical Trials: METREX and MATINEE studies showed significant reduction in exacerbations

This biologic therapy is now available and offers a targeted option for patients whose COPD is driven by eosinophilic inflammation.

▲ Cutting-Edge Clinical Trial: EMP-012 RNA Therapy

A promising new therapy is entering early trials:



"The information provided in this newsletter is for educational and informational purposes only. Any new process, procedure, medication, or clinical trial should be discussed with your primary care physician before being considered or implemented."

Monthly COPD Newsletter

Month/Year: November 2025


EMP-012 – RNA-Based COPD Treatment

- **Developer:** Empirico (licensed to GSK)
- Stage: Phase 1 clinical trial (as of October 2025)
- Mechanism: Uses RNA technology to modulate gene expression
- Target Population: Broad COPD spectrum (not subtype-specific)

EMP-012 represents a potential shift toward disease-modifying treatments at the genetic level.

Therapy Comparison Snapshot

Feature	Nucala (mepolizu <mark>ma</mark> b)	EMP-012 RNA Therapy
Туре	Monoclonal antibody	RNA-based therapy
Status	FDA-approved	Phase 1 clinical trial
Target	Eosinophilic COPD	Broad COPD population
Mechanism	IL-5 inhibition	Gene expression modulation
Developer	GlaxoSmithKline	Empirico / GSK



"The information provided in this newsletter is for educational and informational purposes only. Any new process, procedure, medication, or clinical trial should be discussed with your primary care physician before being considered or implemented."

Monthly COPD Newsletter

Month/Year: November 2025

Local Trial Access: Naples & Fort Myers

If you're interested in participating in COPD research, here are your top local options:

Essence MD Research - Naples, FL

Address: 800 Goodlette-Frank Rd. N #310, Naples, FL 34102

• **Phone:** 239-427-2700

• Website: emdresearch.com

Focus: Phase II–IV trials including respiratory and COPD studies

Statewide Listings

Explore More Trials: PolicyLab COPD Trials in Florida

• Trial Types: Paid studies, Phase 1–4, interventional and observational

Compensation: Some trials offer up to several thousand dollars

How to Get Started

- Contact Essence MD Research to ask about current COPD trials.
- 2. Browse statewide listings for additional opportunities.
- 3. Consult your physician to discuss eligibility and referrals.



"The information provided in this newsletter is for educational and informational purposes only. Any new process, procedure, medication, or clinical trial should be discussed with your primary care physician before being considered or implemented."

Monthly COPD Newsletter

Month/Year: November 2025

Stay informed. Stay involved. We'll be back next month with more information and updates.

Warm Regards,

Naples Pulmonary Rehab Club

www.naplesprclub.com



